Company intelligence / Profile preview
Orocidin
Beverly Hills, California, United Statesorocidin.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Orocidin is advancing QR-01, an antimicrobial peptide therapy targeting inflammation, bacterial infection, and bone regeneration in periodontitis. Toxicity studies are planned for 2025, with a pilot clinical study expected by year-end; no published clinical efficacy data yet.
- Therapeutic areas
- Immunology
- Modalities
- Antimicrobial peptidePeptidesBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Syngene International Limited
Beyond the preview
Go deeper on Orocidin.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orocidin.